A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole

An Open-Label, Parallel-Group, Repeat-Dose Study to Investigate the Effects of End Stage Renal Disease and Haemodialysis on the Pharmacokinetics of Ropinirole (Study RRL103628)

This study will investigate the effects of severe renal impairment and hemodialysis on the characteristics of the drug, ropinirole.

Inclusion:

• Patients and subjects between 18-79 years old.
• End stage renal patients who are consistently receiving dialysis for a minimum of 3.5 hours, three times per week, with hemodialysis blood flow rates of >200mL/min may be eligible to enter the study.
• Patients must also have systolic blood pressure 100-190mmHg and diastolic blood pressure <120mmHg.
• Healthy subjects must have systolic blood pressure 100-150mmHg.

Exclusion:

• Female subjects who are pregnant and/or breast-feeding must not participate in this study.